ArticleFrontiers in cardiovascular medicine2022
Association of
Article in Frontiers in cardiovascular medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 6 citations in OpenAlex.
- Association of the ACE2 rs879922 Polymorphism with Glaucoma Risk and Serum ACE2 Levels.Journal of clinical medicine · 2026Article
- Genetic Analysis and Clinical Effect ofSultan Qaboos University medical journal · 2026Article
- Association of angiotensin-converting enzyme 2 gene polymorphisms with hypertension and treatment response to hydroxychloroquine in Iranian people with coronavirus disease 2019: A cross-sectional study.The Journal of international medical research · 2025Article
- Genetic variations in ACE2 gene associated with metabolic syndrome in southern China: a case-control study.Scientific reports · 2024Article
- Untargeted metabolomics uncovers metabolic dysregulation and tissue sensitivity in ACE2 knockout mice.Heliyon · 2024Article
- Molecular Study ofArchives of Razi Institute · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: In the cardiovascular (CV) system, overactivation of the angiotensin converting enzyme (ACE) may trigger deleterious responses derived from angiotensin (Ang)-II, which can be attenuated by stimulation of ACE2 and subsequent Ang-(1-7) metabolite. However, Methodology: Five Results: Girls ( Conclusion: The expression and activity of ACE2 may be essential for CV homeostasis. Interestingly, the
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.